Imlygic (Talimogene Laherparepvec)

Imlygic (talimogene laherparepvec) is a genetically modified oncolytic viral therapy used for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after the initial surgery.

Limitations of use: This therapeutic drug has not been shown to improve overall survival or have an effect on visceral metastases.

Recommended Dosage: The recommended- starting dose is up to a maximum of 4 mL of Imlygic at a concentration of 106 (1 million) plaque-forming units (PFU) per mL administered by injection into cutaneous, subcutaneous, and/or nodal lesions. Subsequent doses should be administered up to 4 mL of Imlygic at a concentration of 108 (100 million) PFU per mL.

• Accidental exposure to Imlygic, a genetically modified oncolytic viral therapy, can pose significant risks. Healthcare providers should use appropriate personal protective equipment (PPE) to prevent contact with the medication. If accidental exposure occurs, affected areas should be immediately washed with soap and water or disinfectant. Avoid exposure to open wounds or mucous membranes, as the virus can spread to healthy tissues.
  
• Patients treated with Imlygic injection may be at risk of developing herpetic infections due to its basis on a modified herpes simplex virus. Signs of herpetic infection include blisters or sores around the injection site or other body parts. Patients and close contacts, especially those who are immunocompromised, should be monitored for herpetic lesions, and antiviral medications should be administered promptly if an infection is suspected.
  
• Injection site reactions are common and can range from mild pain and erythema to severe ulceration and necrosis. Patients should be monitored for signs of inflammation, infection, and tissue damage. Proper injection techniques and site rotation are recommended to minimize complications. 
  
• Imlygic may trigger immune-mediated events, including autoimmune disorders. Patients should be closely monitored for symptoms of immune system dysregulation, such as rash, fatigue, or joint pain. Immediate medical attention is required if severe immune-mediated adverse events are suspected.
  
• There have been reports of plasmacytoma development at the injection site. Patients with a history of plasma cell disorders should be monitored closely for new or worsening symptoms, and any suspicious lesions should be evaluated promptly.
  
• This therapeutic drug can cause airway obstruction due to inflammation or swelling, particularly when injected near the head and neck. Patients with pre-existing respiratory conditions should be assessed for any breathing difficulties and receive appropriate interventions if necessary.
  
• Treatment with this medicinal product may pose risks to pregnant or breastfeeding women due to potential viral transmission and teratogenic effects. Women of childbearing potential should use effective contraception during treatment and for at least three months after the last dose.
  
• Breastfeeding is not recommended during treatment with Imlygic, as the virus may be present in breast milk. Patients should discuss pregnancy and breastfeeding concerns with their healthcare provider before starting treatment.

What documents are required to import IMLYGIC to India?

IMLYGIC (talimogene laherparepvec) suspension for intralesional injection can be imported by patients or government hospitals in the patients’ name only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

IMLYGIC (talimogene laherparepvec) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Imlygic in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of IMLYGIC (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Imlygic injection price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source the IMLYGIC (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Imlygic®?

Talimogene laherparepvec is a Generic Name for the trade name drug Imlygic®.

What is the Manufacturer’s Name of Imlygic®?

Imlygic® is manufactured by Amgen Inc.

Is Imlygic® approved by the FDA?

Yes, Imlygic® is approved by the FDA. Date of first approval: October 27, 2015.

What is the dosage and form of Imlygic® supplied?

Imlygic® is supplied as an injection: 106 (1 million) PFU per mL, 108 (100 million) PFU per mL in single-use vials for intralesional injection.

What are the most common side effects of Imlygic®? 

The most common infusion-related side effects of Imlygic® are influenza-like illness, fatigue, pyrexia, chills, nausea, and injection site pain.

How much does Imlygic® cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Imlygic in India, it is recommended that you Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Imlygic® be available in SAARC countries? 

Apart from Gulf countries, Imlygic can be available in SAARC countries (India, Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the supply of Imlygic in these countries, ensuring access to this therapeutic drug through legal and reliable channels.

What are the storage conditions of Imlygic®?

Store and transport this therapeutic drug at −90°C to −70°C (−130°F to −94°F). Protect it from light. Store it in the carton until use.